CYCLOPHARM LIMITED — Director's Dealing 2026

Apr 6, 2026

Appendix 3Z Final Director’s Interest Notice

Rule 3.19A.3

Appendix 3Z

Final Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of entity Cyclopharm Limited ABN 74 116 931 250

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	John William Wigglesworth
Date of last notice	12 March 2026
Date that director ceased to be director	6 April 2026

Part 1 – Director’s relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Number & class of securities

88,531 Fully Paid Ordinary Shares

• See chapter 19 for defined terms.

Appendix 3Z Page 1

11/3/2002

Appendix 3Z Final Director’s Interest Notice

Part 2 – Director’s relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interestNote: Provide details of the circumstances giving riseto the relevant interestn/a	Number & class of securitiesn/a

Part 3 – Director’s interests in contracts

art 3 – Director’s interests in contracts
Detail of contract	n/a
Nature of interest	n/a
Name of registered holder(if issued securities)	n/a
No. and class of securities to whichinterest relates	n/a

• See chapter 19 for defined terms.

Appendix 3Z Page 2

11/3/2002